Global orthobiologics market was valued at USD 5.05 billion in 2015. It is projected to grow 7.5% over the forecast period. As a result of the rise in obesity and accidents, there is an increase in orthopedic procedures. An increasing number of orthopedic procedures is also being driven by the growing geriatric population, which is highly vulnerable to other orthopedic disorders and spinal problems.
Market for Orthobiologics by Product, 2014-2025 (USD Billion).
According to an American Academy of Orthopedic Surgeons 2006 study, the demand for hip and knee replacements is expected to rise up to 174% and 673 respectively over the next 20 year. This remarkable growth in orthopedic procedures is a sign of the high demand for orthobiologics to reduce the above-mentioned issues over the next years.
Moreover, the rise in R&D investments and collaborations with prominent biotechnology and medical device companies has led to the development of advanced orthobiologics. Bone Biologics Corp. was in the development stages of Nell-1, a bone growth stimulator orthobiological drug, in May 2015. This product was developed in collaboration with University of California. The subsequent increase in R&D efforts has led to an expansion of a variety of pipeline products, which is expected to provide this sector with lucrative growth opportunities in future.
Viscosupplementation dominated the orthobiologics market as a product segment in 2015. This large share can be attributed to the widespread availability of these products and their unprecedented acceptance in diseases like osteoarthritis and hip degenerative joint disease.
The high adoption rate is presumed to be a consequence of the benefits associated with viscosupplementation. Viscosupplementation has many benefits, including better knee movement, pain relief, less-invasive procedures, and fewer side effect. This is due to the high demand for minimally invasive operations, which leads to high acceptance among the patient base.
The application segment with the highest share was spinal fusion, which accounted for over 50% in 2015. This is due to spinal fusion's ability to provide high bone stability, rapid healing, and improve long-term spinal disorders.
Market for Orthobiologics by Application, 2015 & 2025 (USD billion)
The application segment is also seeing other benefits, such as faster stimulation of bone-forming cells, shorter hospital stays, and fewer visits. Orthobiologics have a large share of this market due to the availability of third-party insurances and reimbursement for fusion enhancement products. This is believed to be responsible for driving growth.
Hospitals held the largest share of the end-use segment in 2015 Hospitals hold a dominant share of the segment's end-use segment. This is due to their increasing adoption of orthobiological products in many different types of spine and reconstructive surgery. Segment growth will also be driven by specialized patient care and the easy availability of an extensive range of orthobiologics at hospitals.
The segment share was also influenced by high patient turnover, frequent readmissions, large procedures volumes, and high patient turn-around. The supportive infrastructure allows for precise operative procedures which will further increase the potential growth.
In 2015, North America held a significant share of the global market. This is due to the presence of many prominent players who are involved in quality care and new product development strategies. The region's share is also influenced by reimbursement policies for soft tissue healing, fusion enhancement products, and other factors.
Market share in Orthobiologics by Region, 2015 (%)
Over the forecast period, Asia Pacific's regional space will grow at an exponential pace. This is due to rising healthcare spending, disposable income, and physician awareness about the benefits of these products.
The market will also benefit from the growing quality of the healthcare infrastructure, which is expected to provide lucrative growth opportunities. The growth is also being driven by an increase in product launches and increased competition among key industry players.
Bioventus, a hyaluronic-based single-injection for joint fluid osteoarthritis treatment, launched DUROLANE in Taiwan in January 2016. The company's increased geographic presence was aided by the launch of DUROLANE, a single-injection hyaluronic acid-based treatment for joint-fluid osteoarthritis. It also helped to increase the market penetration of orthobiological products throughout the Asia Pacific region.
Medtronic, Stryker Corporation, DePuy Synthes, Inc., Genzyme, Smith & Nephew plc, Stryker Corporation, Stryker Corporation, DePuy Synthes, Inc., are key players in the orthobiologics market. These companies are actively integrating new product development activities and collaborations with distribution enhancement strategies, mergers, acquisitions, as well as product approval.
In May 2016, NuVasive Inc., a U.S. company, launched AttraX Putty, a next-generation biologics technology. It is a synthetic bone transplant, used in postolateral spinal surgery as an autograft extensioner. The product launch was done to increase the product line and give us a competitive edge over other market players.
This report provides an analysis of industry trends and forecasts revenue growth for each sub-segment between 2014 and 2025. Grand View Research has divided the market for orthobiologics on the basis product, region, application, end use, and geography.
Global Orthobiologics Product Outlook (Revenue, USD Billion, 2014 - 2025)
Demineralized Bone Matrix(DBM)
Allograft
Bone Morphogenetic Protein (BMP)
Viscosupplementation
Synthetic Bone Substitutes
Stem Cell Therapy
Global Orthobiologics Application Outlook (Revenue, USD Billion, 2014 - 2025)
Spinal Fusion
Trauma Repair
Reconstructive Surgery
Global Orthobiologics End-use Outlook (Revenue, USD Billion, 2014 - 2025)
Hospitals
Orthopedic Clinics
Orthobiologics Regional Outlook (Revenue USD Billion, 2014-2025)
North America
U.S
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
Middle East and Africa
South Africa
b. Global orthobiologics market was valued at USD 5.16 billion in 2019, and is projected to grow to USD 5.46 billion by 2020.
How is the market for orthobiologics growing?b. Global orthobiologics markets are expected to expand at 6.2% compound annual growth rate between 2019 and 2026, to reach USD 7.75 Billion by 2027.
Which segment had the largest market share in orthobiologics?b. North America was the dominant market for orthobiologics in 2019, with a 47.76% share. This is due to the presence of most of the major players involved in quality care and new product development strategies.
Who are the major players in the orthobiologics marketb. The market for orthobiologics includes Bone Biologics, Corp., Medtronic, Bioventus LLC, Pioneer Surgical Technology, Smith & Nephew plc, Stryker Corporation, DePuy Synthes, Inc., Genzyme, Osiris Therapeutics, Inc., Globus Medical, Wright Medical Technology, Orthofix, Inc., NuVasive, Inc., Zimmer Biomet, as well as Anthrex.
What are the driving factors for the orthobiologics industry?b. The market growth is driven by the increasing number of orthotic procedures worldwide as a result of an increase in accidents and obesity, and a growing geriatric population.
Up Market Research published a new report titled “Orthobiologics Market research report which is segmented by Product (Synthetic Bone Substitutes, Viscosupplementation, DBM, Allograft, BMP), by Application (Reconstructive Surgery, Spinal Fusion), By Players/Companies Stem Cell Therapy, Allograft, Viscosupplementation, Demineralized Bone Matrix(DBM), Synthetic Bone Substitutes, Global Orthobiologics Product Outlook (Revenue USD Billion 2014 - 2025)Demineralized Bone Matrix(DBM)AllograftBone Morphogenetic Protein (BMP)ViscosupplementationSynthetic Bone SubstitutesStem Cell Therapy, Bone Morphogenetic Protein (BMP)”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Attributes | Report Details |
Report Title | Orthobiologics Market Research Report |
By Product | Synthetic Bone Substitutes, Viscosupplementation, DBM, Allograft, BMP |
By Application | Reconstructive Surgery, Spinal Fusion |
By Companies | Stem Cell Therapy, Allograft, Viscosupplementation, Demineralized Bone Matrix(DBM), Synthetic Bone Substitutes, Global Orthobiologics Product Outlook (Revenue USD Billion 2014 - 2025)Demineralized Bone Matrix(DBM)AllograftBone Morphogenetic Protein (BMP)ViscosupplementationSynthetic Bone SubstitutesStem Cell Therapy, Bone Morphogenetic Protein (BMP) |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 210 |
Number of Tables & Figures | 147 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Product (Synthetic Bone Substitutes, Viscosupplementation, DBM, Allograft, BMP), by Application (Reconstructive Surgery, Spinal Fusion).
Orthobiologics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Orthobiologics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Orthobiologics Market Report:
Some other reports from this category!